135 results about "Thymus Glands" patented technology

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and OX40L in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and TSLP biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti-OX40L antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or OX40L.

The invention discloses plant lactobacillus and application thereof in immunoregulation and intestinal environment improvement, and relates to the technical field of microorganisms. The invention provides a strain of plant lactobacillus LIHUO 05, and the preservation number of the plant lactobacillus LIHUO 05 is CGMCC (China General Microbiological Culture Collection Center) No.36240. The invention also provides a preparation method of the plant lactobacillus LIHUO 05. The plant lactobacillus LISUO 05 can be used for promoting macrophages to secrete TNF (Tumor Necrosis Factor)-alpha and IL-1beta; the thermally inactivated strain LIHUO 05 has a certain immunoregulation effect on the body weight, thymus index and TNF-alpha content in serum of immunocompromised mice. Meanwhile, the phytobacterium plantarum LIHUO 05 can change the colon flora structure in the intestinal tract, improve the relative abundance of beneficial bacteria and adjust the variety and number of colon metabolites in the intestinal tract, and has a certain effect of improving the intestinal tract environment.

The application discloses a construction method and application of a thymus organoid, and the method is used in combination with small molecule compounds and small molecule proteins to differentiate pluripotent stem cells into the thymus organoid under a suspension culture condition, and the method can efficiently obtain the thymus organoid which is closer to the natural thymus in structure and function.

The present invention relates to a method for treating aging, and in particular immunosenescence, restoring thymic function and regenerating the thymus in a subject in need thereof, comprising the administration of T cell progenitors comprising CD7+CD34- cells.

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

The application provides a thymus disease risk prediction method and system based on cross-modal feature interaction, which comprises the following steps: respectively preprocessing CT image data, MRI image data and image reports; sequentially performing word segmentation, vector conversion, feature extraction and pooling on the third data, inputting the labeled semantic feature vector into an image generation network to generate a PET-CT image; inputting the first data, the second data and the PET-CT image into the same medical mamba feature extraction network respectively to obtain the first modal feature corresponding to the first data, the second modal feature corresponding to the second data and the third modal feature corresponding to the PET-CT image; performing feature fusion interaction on the first modal feature, the second modal feature and the third modal feature to obtain a fusion feature, and obtaining the thymus disease risk according to the fusion feature. The application can greatly improve the thymus disease prediction accuracy.

The present application belongs to the technical field of animal health care, and particularly relates to a fermented decoction for improving growth and immune function of broilers and a preparation method thereof. The fermented decoction for improving growth and immune function of broilers is prepared from the following raw materials by fermentation according to weight parts: radix codonopsis 8-12 parts, angelica sinensis 3-7 parts, cornus officinalis 8-12 parts, cinnamomum cassia 3-7 parts and portulaca oleracea 3-7 parts. The fermented decoction significantly increases the body weight of broilers, significantly improves the thymus index and spleen index, and increases the IgG and IgM contents in serum, thereby promoting the growth of broilers and improving the immune function of broilers. The preparation method of the fermented decoction is simple, and is suitable for industrialized production and market promotion and application.

Disclosed in the present invention are an antibody capable of binding to human thymic stromal lymphopoietin (hTSLP), a preparation method therefor and an application thereof. The anti-hTSLP antibody of the present invention can specifically bind to a hTSLP receptor, has a good effect of inhibiting the secretion of TARC by PBMC, and can be applied to the treatment of TSLP-related diseases, such as immune-mediated inflammatory diseases.

The invention relates to the field of biological medicines, and discloses an application of an anti-thymocyte immune globulin preparation in liver transplantation immune induction, which comprises a use method and a dosage of anti-thymocyte immune globulin as an immune inducer in a liver transplantation recipient. Clinical cases prove that liver transplantation recipients use the anti-thymocyte immune globulin as immunosuppressive induction, so that the liver function and lymphocyte level can be quickly recovered to normal ranges, no obvious influence is caused on renal function, the occurrence rate of acute rejection reaction is reduced, the cytomegalovirus infection rate is not increased, and the anti-thymocyte immune globulin can be applied to liver transplantation recipients. Clinical application of the anti-thymocyte immune globulin in immune induction treatment of liver transplantation recipients is expanded, and the anti-thymocyte immune globulin has a great application prospect.

The application belongs to the technical field of medicines, and specifically provides application of Phanginin A in preparation of medicines for preventing and / or treating skin diseases. The skin diseases include atopic dermatitis and skin epidermal barrier damage. The application finds that Phanginin A can reduce atopic dermatitis lesion scores, improve atopic dermatitis skin pathological thickening and inflammatory cell infiltration, reduce spleen inflammatory response, inhibit volume increase, promote thymus function recovery, down-regulate expression of atopic dermatitis related inflammatory factors IL-6 and TNF-alpha, and can be used for preventing and / or treating atopic dermatitis. In addition, the application also finds that Phanginin A can promote keratinocyte scratch healing, and can be used for repairing skin epidermal barrier damage.

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13 in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP and IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti-IL-13 antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or IL-13.

The present invention relates to a product derived from allogeneically cultured postnatal thymus tissue for use in a method of inducing thymopoiesis and thereby promoting donor-specific tolerance to an allogeneic solid organ transplant in a recipient requiring a solid organ transplant, such as a heart, lung, liver, or other solid organ or part of a whole solid organ. The product derived from allogeneically cultured postnatal thymus tissue is prepared by subjecting suitable thymus tissue to a conditioning regimen, said conditioning regimen comprising the aseptic processing of the donor thymus tissue in a thymus organ medium and producing sections of donor thymus tissue partially devoid of T cells. The method of preparing the allogeneically cultured postnatal thymus tissue is further disclosed.

The application discloses an immune function enhancing composition which is mixed by sambucus williamsii alcohols extract and lactobacillus rhamnosus agent. The application can effectively immunize the spleen, improve the spleen index and thymus index, has the function of immune regulation, and can also improve the IgM and IgG content in serum.

This invention discloses a universal detection method for tumor antigen-specific thymus-dependent lymphocytes in a broad population of East Asia, applicable to lung cancer and gastrointestinal cancers. The broad-spectrum T-cell epitope peptide library used in this detection method contains specific antigen T-cell epitope peptides presented by 13 HLA-A molecules, 15 HLA-B molecules, and 14 HLA-C molecules with an allele frequency greater than 1% in the East Asian population. The total gene frequencies of these dominant HLA-A, B, and C molecules account for approximately 95%, 71%, and 93% of the Chinese population, respectively, and are similar in total gene frequencies in Northeast and Southeast Asian populations. Therefore, this detection method is applicable to the vast majority of individuals in this region, providing a universal method for evaluating specific tumor antigen-specific T-cell immune function in patients with lung cancer or gastrointestinal tumors.

Described herein are compositions and combinations comprising an antibody or antigen binding fragment thereof that binds thymic stromal lymphopoietin (TSLP), an antibody or antigen binding fragment thereof that binds Interleukin-4 Receptor Alpha (IL-4Ra), and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

The invention provides skin anti-inflammatory application of cyclic polypeptide, the polypeptide contains SEQ ID NO: 1, and disulfide bonds at the head and the tail of the polypeptide are cyclized. The skin anti-inflammatory agent disclosed by the invention comprises the step of inhibiting the expression of thymic stromal lymphopoietin (TSLP), interleukin-13 (IL-13), interleukin-31 (IL-31) and / or interleukin-33 (IL-33). The invention also relates to an application of the cyclic polypeptide in preparation of medicines or external skin preparations for preventing and / or treating Th2 type immune related diseases. The external skin preparations are selected from face cream, emulsion, gel, toning lotion, essence, masks, eye cream, aerosol cleaning foam, spray, shower gel or facial cleanser.

The invention belongs to the technical field of experimental animal models, biomedical research and immunology, and discloses a photocoagulation thymus ischemia animal model, a method and application of the photocoagulation thymus ischemia animal model in rapid simulation of thymus degeneration and immune senescence, and the model shows at least one or more characteristics 1-7 days after induction: thymus atrophy, thymus weight or thymus index is significantly reduced; the cortical-medullary structure of thymus is disordered or disappears; the expression distribution of the Keratin 5 / Keratin 8 is abnormal; thymic cell apoptosis is increased, and lipid deposition is enhanced; the proportion of CD4 + CD8 + double positive T cells is reduced, and the proportion of DN2 / DN3 stage T cells is increased; the initial T cell output is reduced; and the immune function is reduced. The pathological mechanism is clear; the modeling period is short, and the immune senescence phenotype can be stably obtained within several days; the injury focus is controllable, and systemic stress or hormone interference is avoided; the model has high repeatability and is suitable for mechanism research and drug screening.

The present disclosure, relates, in general, to methods of treating chronic obstructive pulmonary disease (COPD) using an antibody specific for thymic stromal lymphopoietin (TSLP).

The present invention provides thymic T regulatory cells (ThyTreg cells) that encode or alternatively express a chimeric antigen receptor (CAR) comprising an extracellular domain, a hinge region, a transmembrane domain, and an intracellular domain, wherein the intracellular domain comprises a cytoplasmic costimulatory domain having a sequence having at least 85% identity with SEQ ID NO: 1, and a cytoplasmic stimulatory domain. The present invention also provides compositions and uses in immunotherapy.

Disclosed herein are methods of treating a subject having diabetes mellitus with a population of cells expressing ISL1 and one or more immunosuppressive agents, such as anti-thymosin binding moieties.

The invention discloses herbal paste for enhancing immunity of children as well as a preparation method and application thereof, and relates to the technical field of traditional Chinese medicines. The herbal paste comprises the following components in parts by weight: 3-6 parts of sea-buckthorn, 8-12 parts of longan aril, 3-6 parts of gordon euryale seed, 8-12 parts of dogwood, 3-6 parts of endothelium corneum gigeriae galli, 12-16 parts of Chinese yam, 3-6 parts of astragalus membranaceus, 18-22 parts of Chinese date and 3-6 parts of poria cocos. According to the herbal ointment, by optimizing the components and the preparation method, the concentration of IFN-gamma in blood can be effectively increased, the thymus index is increased, then the immunity of the organism is enhanced, the components of the herbal ointment are safe, and the herbal ointment has good application prospects in products for improving the immunity of children.

Provided are human anti-thymocyte globulin (ATG) products, and methods of making and using the same. In particular, the disclosure provides an ungulate-derived polyclonal immunoglobulin, comprising a population of fully human or substantially human immunoglobulins. The population of fully human or substantially human immunoglobulins specifically binds human thymocytes, T cells, B cells, and / or monocytes. Such compositions may be made by immunization of transgenic animals having a human Ig locus with human thymocytes. This method generates polyclonal immunoglobulin with yield, purity, and antigen specificity that enable the use of this product in medical applications.

A preloaded inhaler comprises a spin chamber in which a primary recess is configured to receive air to mix with contents of a capsule. The primary recess has a curved wall configured to allow rotation of the capsule. A secondary recess is configured to hold the capsule and is located within a bottom surface of the primary recess. A curved inlet channel allows air to travel therethrough. The curved inlet channel defines a curved recess and comprises a tangential section and a funnel section. A capsule containing a dry powder formulation which comprises an antigen binding fragment of an anti-thymic stromal lymphopoietin (TSLP) antibody is held in the spin chamber.

The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for reducing adverse reactions after radiotherapy and chemotherapy of tumor patients and a preparation method thereof, comprising the following components in parts by weight: Radix Bupleuri 6-9 parts, Radix Paeoniae Alba 6-9 parts, Rhizoma Atractylodis Macrocephalae 6-9 parts, Poria 6-9 parts, Angelica sinensis 6-9 parts, Zingiber officinale 3 parts, Radix Rehmanniae Recens 3-6 parts, Gardenia 3-6 parts, Radix Paeoniae Rubra 3-6 parts, Radix Paeoniae Alba 12-20 parts, Rhizoma Chuanxiong 6 parts, and Radix Glycyrrhizae 3-6 parts; the traditional Chinese medicine composition can improve the spirit and movement state of mice, and the weight and food intake of mice are obviously increased, the number of dead mice is significantly reduced, and the tumor volume and weight of mice are significantly reduced; the spleen and thymus indexes, the number of white blood cells, red blood cells and platelets in peripheral blood, and the hemoglobin content are all significantly increased; the number of bone marrow cells and the CD4 + T / CD8 + T cell ratio in peripheral blood are all significantly increased; when applied to clinical patients, the traditional Chinese medicine composition can reduce adverse reactions after radiotherapy and chemotherapy of tumor patients, and has a broad application prospect.

The application discloses a tetrastigma hemsleyanum extract, a preparation method thereof and a medicine for preventing and treating thymic atrophy, and the tetrastigma hemsleyanum extract is prepared by the following steps: crushing dried tetrastigma hemsleyanum plants, extracting by ethanol reflux, and concentrating under reduced pressure to obtain a tetrastigma hemsleyanum crude extract; dissolving the tetrastigma hemsleyanum crude extract in water, extracting by n-butanol, and recovering the solvent to obtain the tetrastigma hemsleyanum extract. The tetrastigma hemsleyanum extract can obviously improve thymic atrophy and has a good anti-thymic atrophy effect, and therefore has great clinical significance and practical value for exploring a new method for preventing and / or treating thymic atrophy and expanding the application range of the tetrastigma hemsleyanum.

The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), and methods of using the dry powder formulations to treat asthma, suitably via pulmonary delivery.

Provided herein are methods of using mesenchymal stromal / stem cell (MCS) exosomes in the treatment of diseases associated with thymic dysfunction. In some embodiments, the MSC exosomes restore thymic architecture and development in a subject having thymic dysfunction (e.g., caused by exposure to hyperoxia). In some embodiments, the subject is a human subject (e.g., a human neonate).

The invention relates to high-purity thymine, a process of purification of thymine, a process for preparing high-purity deoxythymidine, pharmaceutical compositions containing high-purity deoxythymidine and deoxycytidine as well as their use as pharmaceuticals for treatment of mitochondrial depletion syndromes in a mammal.